Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
HOT HOT PENNY
(Total Views: 143)
Posted On: 05/17/2021 12:56:00 PM
Post# of 27150
Avatar
Posted By: budfoxfun
$CURR News Alert: CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an operational update for the first quarter ended March 31, 2021.

First Quarter 2021 and subsequent weeks highlights:

Total revenue rose more than 400% to $1.5 million compared with a year ago and gross profit rose in line with revenue growth.

Received approval for an Investigational New Drug (IND) application from the U.S. Food and Drug Administration and initiated clinical trials for CUREfilm Blue™, an oral soluble film of sildenafil citrate to treat erectile dysfunction.

Commenced clinical development of novel delivery vehicles for certain psychedelic compounds including psilocybin, LSD, and MDMA, which are known to treat a variety of mental health disorders.

Through its Sera Labs subsidiary, launched a new line of Nutri-Strips™ vitamins and supplements that utilize CURE’s proprietary technology, and which are being sold direct to consumer, including via Amazon.

Subsequent to quarter’s end, on May 6, 2021 received a $2.3 million payment related to a contract dispute that was resolved in April.

"During the first quarter, we made good headway on a number of important fronts," said Rob Davidson, CURE Pharmaceutical CEO. "We advanced the clinical development of two of our newest programs, one for an antiviral active pharmaceutical ingredient (API) in which we will apply our patented CUREfilm® delivery platform to optimize the delivery for certain indications. The other will explore the application of a known anti-seizure API to treat adult and pediatric patients who suffer from its debilitating effects. As part of our recently announced psychedelic and antiviral clinical development, these programs are exciting because they leverage existing safety and toxicity data. We believe this will allow us to more quickly develop orally bioavailable treatments and expand our specialty pharmaceutical pipeline. We look forward to talking with shareholders in more detail at our H.C. Wainwright investor presentation on June 17.

(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site